CN117529320A - 用于治疗病毒感染的rock2抑制剂 - Google Patents

用于治疗病毒感染的rock2抑制剂 Download PDF

Info

Publication number
CN117529320A
CN117529320A CN202280030027.8A CN202280030027A CN117529320A CN 117529320 A CN117529320 A CN 117529320A CN 202280030027 A CN202280030027 A CN 202280030027A CN 117529320 A CN117529320 A CN 117529320A
Authority
CN
China
Prior art keywords
ring
group
membered
hours
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280030027.8A
Other languages
English (en)
Chinese (zh)
Inventor
S·D·瓦克萨尔
R·吴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Greweton Biotechnology Co ltd
Original Assignee
Greweton Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Greweton Biotechnology Co ltd filed Critical Greweton Biotechnology Co ltd
Publication of CN117529320A publication Critical patent/CN117529320A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202280030027.8A 2021-02-22 2022-02-22 用于治疗病毒感染的rock2抑制剂 Pending CN117529320A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163152260P 2021-02-22 2021-02-22
US63/152260 2021-02-22
PCT/US2022/017312 WO2022178420A1 (en) 2021-02-22 2022-02-22 Rock2 inhibitor for the treatment of viral infection

Publications (1)

Publication Number Publication Date
CN117529320A true CN117529320A (zh) 2024-02-06

Family

ID=82931820

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280030027.8A Pending CN117529320A (zh) 2021-02-22 2022-02-22 用于治疗病毒感染的rock2抑制剂

Country Status (8)

Country Link
US (1) US20240165116A1 (cg-RX-API-DMAC7.html)
EP (1) EP4301132A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024507414A (cg-RX-API-DMAC7.html)
KR (1) KR20240009918A (cg-RX-API-DMAC7.html)
CN (1) CN117529320A (cg-RX-API-DMAC7.html)
AU (1) AU2022224669A1 (cg-RX-API-DMAC7.html)
CA (1) CA3209240A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022178420A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202327608A (zh) * 2021-09-17 2023-07-16 北京泰德製藥股份有限公司 治療病毒感染的方法
CA3231781A1 (en) * 2021-09-18 2023-03-23 Beijing Tide Pharmaceutical Co., Ltd. Solid form of rho-associated protein kinase inhibitor or solvate thereof, preparation method and use thereof
US12637461B2 (en) 2022-10-18 2026-05-26 Pfizer Inc. Compounds for the activation of AMPK
WO2024220173A1 (en) * 2023-04-18 2024-10-24 Genosco Inc. Blood brain barrier penetrating selective inhibitors of rock2 protein kinases and uses thereof
EP4698528A1 (en) * 2023-04-18 2026-02-25 Genosco Inc. Selective inhibitors of rock2 protein kinases and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015025172A1 (en) * 2013-08-22 2015-02-26 Mark David Charles 5-aryl-thiazol-2-yl-amine compounds and their therapeutic use
EP3308786A1 (en) * 2016-10-13 2018-04-18 ETH Zurich Fgfr regulaton for the treatment of viral infections
CN108699078A (zh) * 2016-03-02 2018-10-23 吉利德阿波罗公司 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法
US20190276440A1 (en) * 2017-06-30 2019-09-12 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
CN120548182A (zh) * 2022-07-27 2025-08-26 格雷威顿生物科技有限公司 用于治疗病毒感染的rock2抑制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3470137A (en) * 1967-02-14 1969-09-30 Du Pont Inter se copolymers of bicyclo(1.1.0)butanes
JP6593305B2 (ja) * 2016-11-09 2019-10-23 株式会社村田製作所 二次電池用電解液、二次電池、電池パック、電動車両、電力貯蔵システム、電動工具および電子機器
TWI804743B (zh) * 2019-06-25 2023-06-11 大陸商北京泰德製藥股份有限公司 治療特發性肺纖維化的方法
CN118772118A (zh) * 2020-08-31 2024-10-15 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂的盐、其固体形式及其制备方法和用途
CA3231781A1 (en) * 2021-09-18 2023-03-23 Beijing Tide Pharmaceutical Co., Ltd. Solid form of rho-associated protein kinase inhibitor or solvate thereof, preparation method and use thereof
EP4434513A4 (en) * 2021-11-16 2025-11-19 Beijing Tide Pharmaceutical Co Ltd NANOCRYSTALLINE PREPARATION OF ROCK2 INHIBITOR AND ITS PREPARATION PROCESS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015025172A1 (en) * 2013-08-22 2015-02-26 Mark David Charles 5-aryl-thiazol-2-yl-amine compounds and their therapeutic use
CN108699078A (zh) * 2016-03-02 2018-10-23 吉利德阿波罗公司 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法
EP3308786A1 (en) * 2016-10-13 2018-04-18 ETH Zurich Fgfr regulaton for the treatment of viral infections
US20190276440A1 (en) * 2017-06-30 2019-09-12 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
CN120548182A (zh) * 2022-07-27 2025-08-26 格雷威顿生物科技有限公司 用于治疗病毒感染的rock2抑制剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KOCH JC, TÖNGES L, BARSKI E, MICHEL U, BÄHR M, LINGOR P.: "ROCK2 is a major regulator of axonal degeneration, neuronal death and axonal regeneration in the CNS", 《CELL DEATH DIS.》, vol. 15, no. 5, 15 May 2014 (2014-05-15), pages 1 - 12 *

Also Published As

Publication number Publication date
JP2024507414A (ja) 2024-02-19
WO2022178420A1 (en) 2022-08-25
KR20240009918A (ko) 2024-01-23
CA3209240A1 (en) 2022-08-25
US20240165116A1 (en) 2024-05-23
EP4301132A4 (en) 2025-03-26
AU2022224669A1 (en) 2023-09-28
EP4301132A1 (en) 2024-01-10

Similar Documents

Publication Publication Date Title
US20240165116A1 (en) Rock2 inhibitor for the treatment of viral infection
RU2640485C2 (ru) Комбинированное лечение рака
US6384039B1 (en) QT dispersion and heart rate variability improvement with CRF antagonists to prevent sudden death
AU2012321106B2 (en) Administration of NEDD8-activating enzyme inhibitor and hypomethylating agent
JP6440212B2 (ja) メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用
KR101996245B1 (ko) 선택적 s1p1 수용체 아고니스트를 포함하는 약학 조합물
CN114026072A (zh) 治疗特发性肺纤维化的方法
AU2008284364A1 (en) Use of phosphatases to treat neuroblastomas and medulloblastomas
JP2023109899A (ja) 少なくとも1つのスプライソソームモジュレーターと、bcl2阻害剤、bcl2/bclxl阻害剤及びbclxl阻害剤から選択される少なくとも1つの阻害剤とを含む組合せ、並びに使用の方法
CN111343986A (zh) 用于治疗纤维化疾病的化合物及其药物组合物
HRP20040619A2 (en) Combination of cytochome p<sub>450</sub> dependent protease inhibitors
BR112021000938A2 (pt) composto sal farmaceuticamente aceitável, tautômero, isômero ou estereoisômero do mesmo, composição farmacêutica e processo para a síntese do dito composto
TW201636049A (zh) 組合癌症療法
US20240041861A1 (en) Compositions and methods for treatment and prophylaxis of viral infections
US20260007673A1 (en) Rock2 inhibitors for the treatment of viral infections
BRPI0616659A2 (pt) droga terapÊutica antituberculose, medicamento, e, kit para o tratamento de tuberculose
WO2014208354A1 (ja) 炎症性疾患を治療又は予防するための医薬組成物
CN114072205A (zh) 用tie-2激活剂治疗高血压的方法
CN118678960A (zh) 用于治疗癌症的方法和组合物
JP2024518426A (ja) 投与レジメン
Ilango et al. Roflumilast: an upcoming drug for curing asthma and COPD
TW202327608A (zh) 治療病毒感染的方法
HK40031991A (en) Methods of treating and preventing graft versus host disease
HK40063597A (en) Methods of treating hypertension with activators of tie-2
HK40006418A (en) Combinations and methods comprising a capsid assembly inhibitor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination